Gamma-aminobutyric acid type A receptor benzodiazepine site (non-alpha1 subtypes) (GABAAR-BZ (non-alpha1))

The GABA-A receptor benzodiazepine site on non-alpha1 subtypes refers to the allosteric binding pocket located at the interface of the gamma2 subunit and the alpha2, alpha3, or alpha5 subunits of the pentameric GABA-A receptor. While the alpha1 subunit is primarily responsible for the sedative, hypnotic, and amnestic effects of classical benzodiazepines like diazepam, the non-alpha1 subtypes mediate distinct physiological responses. Specifically, alpha2 and alpha3 subunits are the principal mediators of anxiolytic and analgesic effects, whereas the alpha5 subunit is largely localized in the hippocampus and regulates tonic inhibition related to learning and memory. Targeting these specific subtypes allows for the development of "anxioselective" or "non-sedating" therapies that provide relief from anxiety, pain, or seizures without the debilitating motor impairment and sedation associated with broad-spectrum GABA-A modulators. Positive allosteric modulators (PAMs) selective for alpha2 and alpha3 are currently being investigated for generalized anxiety disorder and epilepsy, while negative allosteric modulators (NAMs) of the alpha5 site are explored as potential cognitive enhancers for conditions such as Down syndrome and schizophrenia. This subtype-selective approach aims to improve the therapeutic window and reduce the abuse liability and tolerance issues characteristic of traditional benzodiazepine therapy.

Other names

GABAA receptor benzodiazepine site on non-alpha1 BZ-sensitive subtypesAlpha2/alpha3/alpha5-selective GABA-A receptor benzodiazepine siteNon-sedating benzodiazepine receptor siteGABRA2/GABRA3/GABRA5 benzodiazepine binding site

Positive allosteric modulation (PAM) of alpha2, alpha3, or alpha5 subunit-containing receptors to enhance inhibitory GABAergic signaling; or negative allosteric modulation (NAM) of alpha5 subunit-containing receptors to reduce tonic inhibition and enhance cognition.